Jeff Auxier's ABT Position Overview
Jeff Auxier (via Auxier Asset Management LLC) currently holds 67.2K shares of Abbott Laboratories (ABT) worth $8.99 M, representing 1.26% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Jeff Auxier has maintained a long-term strategic position in ABT, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2017, adding 29.3K shares. Largest reduction occurred in Q2 2020, reducing 5.6K shares.
Analysis based on 13F filings available since 2013 Q2
Jeff Auxier's Abbott Laboratories (ABT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Abbott Laboratories (ABT) Trades by Jeff Auxier
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +80,491 | Add 0.00% | 80,490 | $34.87 |
| Q2 2014 | -819 | Reduce 1.02% | 79,671 | $40.91 |
| Q3 2014 | -300 | Reduce 0.38% | 79,371 | $41.59 |
| Q4 2014 | -500 | Reduce 0.63% | 78,871 | $45.02 |
| Q1 2015 | -1,000 | Reduce 1.27% | 77,871 | $46.33 |
| Q2 2015 | -50 | Reduce 0.06% | 77,821 | $49.07 |
| Q3 2015 | +1,101 | Add 1.41% | 78,922 | $40.22 |
| Q1 2016 | -250 | Reduce 0.32% | 78,672 | $41.83 |
| Q3 2016 | -50 | Reduce 0.06% | 78,622 | $42.29 |
| Q4 2016 | +42 | Add 0.05% | 78,664 | $38.40 |
| Q1 2017 | +29,349 | Add 37.31% | 108,013 | $44.41 |
| Q2 2017 | +301 | Add 0.28% | 108,314 | $48.61 |
| Q3 2017 | -149 | Reduce 0.14% | 108,165 | $53.36 |
| Q4 2017 | -3,779 | Reduce 3.49% | 104,386 | $57.07 |
| Q1 2018 | -251 | Reduce 0.24% | 104,135 | $59.92 |
| Q2 2018 | -2,279 | Reduce 2.19% | 101,856 | $60.99 |
| Q3 2018 | -299 | Reduce 0.29% | 101,557 | $73.36 |
| Q4 2018 | -1,199 | Reduce 1.18% | 100,358 | $72.33 |
| Q1 2019 | -1,929 | Reduce 1.92% | 98,429 | $79.94 |
| Q2 2019 | -1,049 | Reduce 1.07% | 97,380 | $84.10 |
| Q3 2019 | +300 | Add 0.31% | 97,680 | $83.67 |
| Q4 2019 | -229 | Reduce 0.23% | 97,451 | $86.86 |
| Q1 2020 | -3,954 | Reduce 4.06% | 93,497 | $78.91 |
| Q2 2020 | -5,552 | Reduce 5.94% | 87,945 | $91.43 |
| Q3 2020 | -1,737 | Reduce 1.98% | 86,208 | $108.83 |
| Q4 2020 | -415 | Reduce 0.48% | 85,793 | $109.48 |
| Q1 2021 | -648 | Reduce 0.76% | 85,145 | $119.84 |
| Q2 2021 | -905 | Reduce 1.06% | 84,240 | $115.93 |
| Q3 2021 | -2,678 | Reduce 3.18% | 81,562 | $118.13 |
| Q4 2021 | -4,256 | Reduce 5.22% | 77,306 | $140.74 |
| Q1 2022 | -19 | Reduce 0.02% | 77,287 | $118.36 |
| Q2 2022 | -999 | Reduce 1.29% | 76,288 | $108.65 |
| Q3 2022 | -950 | Reduce 1.25% | 75,338 | $96.76 |
| Q4 2022 | -159 | Reduce 0.21% | 75,179 | $109.79 |
| Q1 2023 | -2,808 | Reduce 3.74% | 72,371 | $101.26 |
| Q2 2023 | +2,371 | Add 3.28% | 74,742 | $109.02 |
| Q3 2023 | -1,295 | Reduce 1.73% | 73,447 | $96.85 |
| Q4 2023 | -809 | Reduce 1.10% | 72,638 | $110.07 |
| Q1 2024 | -1,538 | Reduce 2.12% | 71,100 | $113.66 |
| Q2 2024 | -20 | Reduce 0.03% | 71,080 | $103.91 |
| Q3 2024 | -41 | Reduce 0.06% | 71,039 | $114.01 |
| Q4 2024 | -1,300 | Reduce 1.83% | 69,739 | $113.11 |
| Q1 2025 | -1,182 | Reduce 1.69% | 68,557 | $132.65 |
| Q2 2025 | -805 | Reduce 1.17% | 67,752 | $136.01 |
| Q3 2025 | -599 | Reduce 0.88% | 67,153 | $133.94 |
Jeff Auxier's Abbott Laboratories Investment FAQs
Jeff Auxier first purchased Abbott Laboratories (ABT) in Q2 2013, acquiring 80,490 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeff Auxier has held Abbott Laboratories (ABT) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeff Auxier's largest addition to Abbott Laboratories (ABT) was in Q2 2013, adding 80,490 shares worth $2.81 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Jeff Auxier's firm, Auxier Asset Management LLC, owns 67,153 shares of Abbott Laboratories (ABT), valued at approximately $8.99 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Abbott Laboratories (ABT) represents approximately 1.26% of Jeff Auxier's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeff Auxier's peak holding in Abbott Laboratories (ABT) was 108,314 shares, as reported at the end of Q2 2017. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.